Insmed/$INSM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Insmed
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
- Ticker
- $INSM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,664
- Headquarters
- Bridgewater, United States
- Website
- www.insmed.com
Insmed Metrics
BasicAdvanced
$21B
-
-$4.08
0.82
-
Price and volume
Market cap
$21B
Beta
0.82
52-week high
$212.75
52-week low
$90.39
Average daily volume
2.5M
Financial strength
Current ratio
3.724
Quick ratio
3.135
Long term debt to equity
0.964
Total debt to equity
0.977
Interest coverage (TTM)
-9.99%
Profitability
EBITDA (TTM)
-794.955
Gross margin (TTM)
83.46%
Net profit margin (TTM)
-76.94%
Operating margin (TTM)
-71.43%
Effective tax rate (TTM)
-0.71%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
-22.17%
Return on equity (TTM)
-87.22%
Valuation
Price to revenue (TTM)
18.264
Price to book
27.89
Price to tangible book (TTM)
40.02
Price to free cash flow (TTM)
-24.368
Free cash flow yield (TTM)
-4.10%
Free cash flow per share (TTM)
-3.972
Growth
Revenue change (TTM)
185.76%
Earnings per share change (TTM)
-28.60%
3-year revenue growth (CAGR)
61.62%
3-year earnings per share growth (CAGR)
-8.18%
10-year earnings per share growth (CAGR)
6.68%
What the Analysts think about Insmed
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Analyst projections of the future price of Insmed stock.
Bulls say / Bears say
BRINSUPRI is off to a strong start: second-quarter revenue reached $309.2 million, up 49% sequentially, and Insmed raised its 2026 revenue outlook to $1.25–$1.40 billion. That gives the company a fast-growing commercial engine. (Insmed)
ARIKAYCE has a potential regulatory catalyst: its Phase 3b ENCORE study met its main and key secondary endpoints, and the FDA granted priority review to Insmed’s application for full approval, with a decision due by 28 January 2027. (PR Newswire)
TPIP offers pipeline upside beyond current products: its 12-month extension study reported sustained improvements across efficacy measures with no newly identified safety signals. Insmed is advancing the candidate in Phase 3 trials across several lung conditions. (PR Newswire)
The growth is still expensive to fund: Insmed used $311.6 million of operating cash in the first half of 2026, while research and selling costs rose 38% year on year in the second quarter. The company has about $1.2 billion in cash and investments, but still expects continued investment and has yet to reach cash-flow positivity. (StockTitan, The Motley Fool)
ARIKAYCE is a relatively slow-growing part of the current portfolio in the US: revenue there was up just 2% in the second quarter and less than 1% in the first half of 2026. This leaves more of the growth case resting on continued BRINSUPRI uptake. (Insmed)
TPIP remains an unproven clinical programme: the positive 12-month results came from an open-label extension without a placebo control, and its Phase 3 PAH study is still under way. Failure to confirm the early signal in controlled trials would weaken this pipeline opportunity. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Insmed Financial Performance
Revenues and expenses
Insmed Earnings Performance
Company profitability
Upcoming events
No upcoming events
Insmed News
AllArticlesVideos
Funds containing Insmed
AllUSDGBPEUR
Fund name | Fund size | $INSM weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.45% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.45% |
Amundi S&P 500£500G | £6.6B | 0.86% |
SPDR MSCI World Health Care$WHEA | $708M | 0.25% |
Xtrackers MSCI World Health Care$XDWH | $4.1B | 0.25% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.